Amicus Therapeutics (NASDAQ:FOLD) Insider David Michael Clark Sells 25,643 Shares of Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) insider David Michael Clark sold 25,643 shares of the company’s stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $9.51, for a total transaction of $243,864.93. Following the sale, the insider directly owned 322,618 shares of the company’s stock, valued at approximately $3,068,097.18. This trade represents a 7.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Amicus Therapeutics Price Performance

Shares of Amicus Therapeutics stock traded up $0.20 during trading on Wednesday, reaching $9.19. 7,012,696 shares of the company’s stock were exchanged, compared to its average volume of 4,167,813. Amicus Therapeutics, Inc. has a 1-year low of $5.51 and a 1-year high of $12.65. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.29 and a current ratio of 3.21. The firm’s 50-day moving average price is $8.22 and its 200 day moving average price is $7.04. The company has a market cap of $2.83 billion, a P/E ratio of -76.58 and a beta of 0.66.

Institutional Trading of Amicus Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Osaic Holdings Inc. boosted its position in shares of Amicus Therapeutics by 450.1% during the 2nd quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 3,358 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Amicus Therapeutics by 472.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 3,677 shares during the period. Strs Ohio bought a new stake in shares of Amicus Therapeutics in the 1st quarter valued at $30,000. Versant Capital Management Inc grew its holdings in Amicus Therapeutics by 499.1% in the third quarter. Versant Capital Management Inc now owns 5,266 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 4,387 shares during the period. Finally, PNC Financial Services Group Inc. increased its stake in Amicus Therapeutics by 211.4% in the first quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 3,497 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities analysts recently commented on FOLD shares. The Goldman Sachs Group increased their price objective on shares of Amicus Therapeutics from $9.00 to $11.00 and gave the company a “neutral” rating in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Amicus Therapeutics in a report on Wednesday, October 8th. Zacks Research upgraded Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. Morgan Stanley upgraded Amicus Therapeutics from an “equal weight” rating to an “overweight” rating in a report on Thursday, July 17th. Finally, Needham & Company LLC raised Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research note on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Amicus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.13.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.